R
RLMD
Relmada Therapeutics Inc
7.29
-0.32-4.21%After Hours: 7.27 -0.02 -0.22%16:53 04/10 EDT
OPEN/PREV CLOSE7.72/7.61
TODAY RANGE7.16-7.94
VOL1.76M
MARKET CAP764.65M
52 WEEK RANGE0.2430-7.94
AVG VOL (3M)1.61M
% TURNOVER1.68%
TURNOVER--
P/E (TTM)-5.0155
% RANGE10.25%
EPS(TTM)-1.4535
P/E(FORWARD)-9.3462
P/B6.18
BVPS1.180
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP457.48M
SHARES OUTSTANDING104.89M
NEXT EARNINGS05/11-05/15
FREE FLOAT62.75M
LOT SIZE1
EX-DATE09/30/2019
News
Press Releases
Financial Reports
Profile
NASDAQ·04/02 14:00
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
Seeking Alpha·03/30 19:16
Relmada Therapeutics: 2 New Assets, 2 New 'Blockbusters'? I'd Wait And See
Reuters·03/30 07:01
PreveCeutical appoints Dr. Raj S. Pruthi to board of directors
Seeking Alpha·03/24 18:31
Relmada wins bullish view at Piper Sandler on cancer therapy
Dow Jones·03/24 13:05
Relmada Therapeutics Price Target Announced at $12.00/Share by Piper Sandler
TipRanks·03/24 09:00
Relmada Therapeutics initiated with an Overweight at Piper Sandler
Reuters·03/24 07:39
U.S. RESEARCH ROUNDUP-Apogee Therapeutics, Insmed, Sunoco
TipRanks·03/21 00:05
Relmada Therapeutics Charts Aggressive Path After Earnings Call
TipRanks·03/20 21:21
Relmada Highlights NDV-01 Data, Funding in 2025 Results
Dow Jones·03/20 13:54
Relmada Therapeutics Price Target Raised to $19.00/Share From $10.00 by Mizuho
Dow Jones·03/20 13:54
Relmada Therapeutics Is Maintained at Outperform by Mizuho
Benzinga·03/20 13:44
Mizuho Maintains Outperform on Relmada Therapeutics, Raises Price Target to $19